U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07213570) titled 'STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer' on Sept. 22.
Brief Summary: The investigators hypothesize that patients with mCRC RAS-mutant eligible for a second line treatment with good prognostic features, identified as single metastatic site, long progression free survival (PFS) in first line treatment, might benefit from a personalized approach, with less intensive treatment with regorafenib as part of a continuum-of-care strategy aimed at ensuring quality of life and extending survival.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
Colorectal Cancer Metastatic...